Browse the evidence

Myonuclear accretion and satellite cell (SC) content did not significantly differ between the MIS and COL groups after 10 weeks of RET.

Both types of supplementation may not significantly affect myonuclear and satellite cell content during resistance training.

Expectancy may have played a partial role influencing strength-endurance in previous studies.

Understanding the role of expectancy can help practitioners optimize training outcomes.

GLP-1RAs can cause gastrointestinal adverse events such as nausea, vomiting, and diarrhea.

Healthcare providers should monitor patients for gastrointestinal side effects when prescribing GLP-1RAs.

GLP-1RAs may lead to treatment discontinuation due to gastrointestinal side effects.

Clinicians should prepare patients for the possibility of discontinuation due to side effects.

A semisupervised high-intensity interval training (HIT) intervention did not increase menstrual frequency in women with polycystic ovary syndrome (PCOS).

Practitioners should note that HIT may not be effective for improving menstrual frequency in women with PCOS.

Significant weight loss induced by caloric restriction and metabolic and bariatric surgery (MBS) results in high turnover bone loss.

Practitioners should be aware that significant weight loss from caloric restriction and MBS can lead to increased bone loss.

Weight loss after metabolic and bariatric surgery (MBS) is associated with a substantial deterioration in bone microarchitecture and strength, increasing fracture risk.

Clinicians should monitor bone health closely in patients undergoing MBS due to increased fracture risk.

Significant weight loss induced by GLP-1 receptor agonists (GLP-1Ra) may result in accelerated bone turnover and bone loss.

Healthcare providers should consider the impact of GLP-1Ra on bone health when prescribing these medications.

The postoperative incidence of beneficial effects and complications from RYGB varies across patient subgroups with different preoperative characteristics.

Individualized assessment of patients is crucial to optimize RYGB outcomes and minimize complications.

Dulaglutide is associated with a significantly higher risk of overall hematologic malignancy (OR = 2.18, 95%CI = 1.14-4.19).

Clinicians should be cautious when prescribing dulaglutide due to its association with increased hematologic malignancy risk.

Severe adverse effects with GLP-1 RA use are not uncommon and warrant further close monitoring.

Practitioners should closely monitor patients for severe adverse effects when initiating GLP-1 RA therapy.

BGM1812 is a novel dual amylin and calcitonin receptor agonist with enhanced efficacy compared to petrelintide.

BGM1812 may be a promising option for obesity treatment.

BGM1812 exhibits excellent performance in terms of half-life, stability, and solubility.

These properties suggest BGM1812 could be a viable therapeutic option.

Solid gastric contents were significantly more frequent in patients receiving semaglutide treatment (42%) compared to controls (7%).

Healthcare providers should consider the higher likelihood of solid gastric contents in patients on semaglutide when planning surgeries.

There is an ongoing debate over the role of pharmacotherapy versus interventional approaches in treating obesity and MASLD in liver transplantation.

Clinicians should stay informed about evolving treatment options for obesity and MASLD.

Experience with GLP-1 agonists in patients with obesity and inflammatory skin diseases is currently scarce.

Further research is needed to establish the efficacy and safety of GLP-1 agonists in this specific population.

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate notable cardiovascular benefits beyond glucose regulation in patients with coronary artery disease (CAD).

Practitioners should consider SGLT2i and GLP-1 RAs for cardiovascular protection in CAD patients.

The interaction between hyperglycemia, endothelial dysfunction, inflammation, and thrombosis contributes to the progression of coronary artery disease (CAD) and its acute complications.

Understanding these interactions can help in developing targeted therapies for CAD.

There has been a shift in the therapeutic approach to coronary artery disease (CAD) in patients with Type 2 Diabetes Mellitus (T2DM).

Healthcare providers should stay updated on evolving treatment strategies for CAD in T2DM patients.

GLP-1a therapy was associated with a mean change in HbA1c of −1.00% (±2.07) in treated patients compared to −0.83% (±1.92) in those without GLP-1a therapy.

GLP-1a therapy may lead to modest reductions in HbA1c in a real-world setting.

GLP-1 receptor agonist patients demonstrated higher overall complication rates (20%) compared to controls (10%), though this was not statistically significant (p=0.47).

Clinicians should be aware of the potential for higher complication rates in patients using GLP-1 receptor agonists.

GLP-1 receptor agonist patients had significantly lower serum albumin (4.06 g/dL) and prealbumin levels (23.52 mg/dL) compared to controls (4.22 g/dL and 25.55 mg/dL, respectively).

Monitoring nutritional status, including serum albumin and prealbumin, may be important for patients on GLP-1 receptor agonists.

The use of semaglutide in patients with previous intake of other AOMs was associated with inferior weight loss outcomes.

Healthcare providers should be cautious when prescribing semaglutide to patients with a history of AOM use, as they may not achieve optimal weight loss.

Tirzepatide dose-dependently reduced voluntary alcohol consumption and prevented binge and relapse-like drinking.

Tirzepatide may help in managing alcohol use disorder by reducing consumption and preventing relapse.